Pharma Mar Forecast, price target & analysts
Pharma Mar Target price 2026 - Analyst rating & recommendation
Pharma Mar Classifications & Recommendation
Pharma Mar Price Target
| Target Price | €102.00 |
| Price | €69.45 |
| Potential |
46.87%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Pharma Mar 2027 .
The average Pharma Mar target price is €102.00.
This is
46.87%
register free of charge
€131.25
88.98%
register free of charge
€63.29
8.87%
register free of charge
|
|
| A rating was issued by 14 analysts: 10 Analysts recommend Pharma Mar to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2027 of
46.87%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 221.39 | 211.02 |
| 26.61% | 4.68% | |
| EBITDA Margin | 29.84% | 21.86% |
| 389.07% | 26.75% | |
| Net Margin | 33.87% | 19.68% |
| 126.67% | 41.90% |
11 Analysts have issued a sales forecast Pharma Mar 2026 . The average Pharma Mar sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Pharma Mar EBITDA forecast 2026. The average Pharma Mar EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Pharma Mar Analysts have issued a net profit forecast 2026. The average Pharma Mar net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 4.30 | 2.40 |
| 188.59% | 44.19% | |
| P/E | 28.64 | |
| EV/Sales | 5.28 |
11 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar EPS is
This results in the following potential growth metrics and future valuations:
Current Pharma Mar Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BANCO SANTANDER |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| CHARDAN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| ALANTRA EQUITIES |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| BESTINVER SECURITIES |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| NEEDHAM & COMPANY INC. |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BANCO SANTANDER:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
CHARDAN CAPITAL MARKETS:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
ALANTRA EQUITIES:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
BESTINVER SECURITIES:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
NEEDHAM & COMPANY INC.:
Locked
➜
Locked
|
Jul 30 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
